The AHF-CORE study is a prospective, non-randomized, multicenter regional study. The main objective of the AHF-CORE study is to identify congestion markers (clinical, biological and ultrasound) at the beginning and at the end of hospitalization for acute heart failure that are more strongly associated with the risk of all cause death or rehospitalization for acute heart failure within 3 months of hospital discharge. Secondary objectives are: * Quantify the variations in congestion markers between the beginning and end of hospitalization for acute heart failure. * Assess the correlation between changes in congestion markers between the beginning and end of hospitalization. * Identify the congestion markers at the beginning of hospitalization that are most strongly associated with residual congestion at the end of hospitalization. * Identify the added value of ultrasound and biological markers of congestion in addition to clinical variables for the prediction of all-cause death or hospitalization for acute heart failure at 3 months after hospital discharge. * Identify the association of ultrasound and biologic congestion markers assessed at admission and final discharge with NYHA class at 3 months after hospital discharge
Congestion (clinical, biological and ultrasound evaluation) will be quantified at inclusion within 72 hours of admission and before hospital discharge. Follow-up at 3 months of hospital discharge will be performed through telephone interviews. Vital status and rehospitalization status will be collected. Throughout the study, patients will continue to be treated according to usual routine care, regardless of their level of congestion. There will be no modification of treatment according to the congestion data acquired within the setting of the study.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
80
Clinical examination centered on congestion will be performed within 72 hours of admission and before discharge from hospital
Cardio-pulmonary and peritoneal ultrasound will be performed within 72 hours of admission and before discharge from hospital
Blood sample collection will be performed within 72 hours of admission and before discharge from hospital
Telephone interview will be performed 3, 12 and 24 months after discharge from hospital
Urinary sample collection will be performed within 72 hours of admission and before discharge from hospital
optional jugular and renal ultrasound performed within 72hours of admission and before discharge from hospital
CHR Metz-Thionville - Hôpital de Mercy
Metz, Lorraine, France
RECRUITINGCHRU Nancy Hôpitaux de Brabois
Vandœuvre-lès-Nancy, Lorraine, France
RECRUITINGRate of all-cause death
composite endpoint: rate of all-cause death, hospitalization for acute heart failure or day-hospital IV diuretics injection for acute HF during 24 months following the day hospitalization (with outcome 2 and 3)
Time frame: at 3 months after hospital discharge
Rate of rehospitalization for acute heart failure
composite endpoint: rate of all-cause death, hospitalization for acute heart failure or day-hospital IV diuretics injection for acute HF during 24 months following the day hospitalization (with outcome 1 and 3)
Time frame: at 3 months after hospital discharge
Rate of day-hospital or at-home IV diuretics injection for acute HF
composite endpoint: rate of all-cause death, hospitalization for acute heart failure or day-hospital IV diuretics injection for acute HF during 24 months following the day hospitalization (with outcome 1 and 2)
Time frame: at 3 months after hospital discharge
Clinical congestion markers as assessed with the Ambrosy Score
Clinical congestion markers as assessed with the Ambrosy Score at admission and at final discharge
Time frame: at admission and at final discharge (an average of 10 days after admission)
Clinical congestion markers as assessed with the ASCEND score
Clinical congestion markers as assessed with the ASCEND score at admission and at final discharge
Time frame: at admission and at final discharge (an average of 10 days after admission)
Natriuretic peptides
Natriuretic peptides at admission and at final discharge
Time frame: at admission and at final discharge (an average of 10 days after admission)
Estimated plasma volume
Estimated plasma volume at admission and at final discharge
Time frame: at admission and at final discharge (an average of 10 days after admission)
Ultrasound congestion markers
B lines, pleural effusion, E/e', DTE, TRV, VCI, Jugular diameter, renal venous blood flow pattern, peritoneal effusion
Time frame: at admission and at final discharge (an average of 10 days after admission)
Residual congestion
as defined as an Ambrosy score 3 or more and/or B-lines score 30 or more and/or an IVC\>21 and IVC collapse with sniff \<50%
Time frame: at final discharge (an average of 10 days after admission)
NYHA class
NYHA class (1, 2, 3, 4)
Time frame: 3 months after hospital discharge
Rate of day-hospital for Intravenous diuretics administration for acute HF
To identify the markers of congestion (clinical, biological, and ultrasonographic), at the end of hospitalization for ICA most strongly associated with the risk of intravenous administration of diuretics in day-hospital for ICA at 3,12, and 24 months after hospital discharge.
Time frame: 3, 12 and 24 months after hospitalization
Rate of all-cause death
composite endpoint: rate of all-cause death, hospitalization for acute heart failure or day-hospital IV diuretics injection for acute HF during 24 months following day hospitalization (with outcome 12 and 13)
Time frame: 12 and 24 months after hospitalization
Rate of hospitalization for acute heart failure
composite endpoint: rate of all-cause death, hospitalization for acute heart failure or day-hospital IV diuretics injection for acute HF during 24 months following day hospitalization (with outcome 11 and 13)
Time frame: 12 and 24 months after hospitalization
Rate of day-hospital or in-home IV diuretics injection for acute HF
composite endpoint: rate of all-cause death, hospitalization for acute heart failure or day-hospital IV diuretics injection for acute HF during 24 months following day hospitalization (with outcome 11 and 12)
Time frame: 12 and 24 months after hospitalization
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.